Home › Compound Library › GLP-1 & Metabolic › Danuglipron
GLP-1 & Metabolic Research Preliminary

Danuglipron

Twice-daily oral small molecule GLP-1 receptor agonist (Pfizer). Studied as pill-format GLP-1 alternative. Phase 3 program paused 2024 due to GI tolerability; research continues on modified release formulations.

GLP-1oralPfizersmall moleculeweight lossBIDtwice-daily
Half-life
~4–6 hours; requires twice-daily dosing
SKUs Available
2
Evidence Level
Preliminary
Mechanism of Action

Small molecule GLP-1 receptor agonist. Distinct binding mode from orforglipron — competitive/orthosteric at GLP-1 receptor orthosteric site. Twice-daily pharmacokinetics reflect shorter half-life than once-daily competitors.

Published Research Ranges & Study Context

Studies have administered: 40–120mg twice daily in phase 2 dose-finding; 120mg BID in phase 3 pivot

Important Research Framing These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings

Phase 2b data: up to 11.7% weight loss at highest dose. GI AEs higher than competitor class. Pfizer development pause announced 2024 for tolerability optimization. Modified release formulation in development.

Preliminary Primarily preclinical + case reports
Side Effects Observed in Research

Higher GI tolerability issues vs competitor oral GLP-1 molecules; nausea, vomiting rates drove phase 3 pause decision

Available Configurations (SKU Reference)
DAN4 DAN12
Compounds Studied in Combination

These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.

Want a Complete Research Monograph?

Our AI can generate a 2,000+ word deep-dive on Danuglipron — including full clinical trial summaries, pharmacokinetics, and research frontiers.

Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.